Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; if barrier contraceptives are being used, these must be continued throughout the trial by both sexes; hormonal contraceptives are not acceptable as a method of contraception; (women of childbearing potential must have a negative urine or serum pregnancy test within  days prior to starting treatment)
Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; if barrier contraceptives are being used, these must be continued throughout the trial by both sexes; hormonal contraceptives are not acceptable as a sole method of contraception; (women of childbearing potential must have a negative urine or serum pregnancy test within  days prior to administration of everolimus)
Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; if barrier contraceptives are being used, these must be continued throughout the trial by both sexes; hormonal contraceptives are not acceptable as a sole method of contraception; (Women of childbearing potential must have a negative urine or serum pregnancy test within  days prior to administration of RAD)
Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; adequate contraception must be used throughout the trial and for  weeks after the last dose of study drug, by both sexes; (females of childbearing potential must have a negative serum pregnancy test within  days prior to administration of axitinib)
Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods as defined above. If barrier contraceptives are being used, these must be continued throughout the trial by both sexes. Hormonal contraceptives are not acceptable as a sole method of contraception.
Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; if barrier contraceptives are being used, these must be continued throughout the trial and for  weeks after stopping study drug, by both sexes; hormonal contraceptives are not acceptable as a sole method of contraception; (women of childbearing potential must have a negative urine or serum pregnancy test within  days prior to administration of EVE)
Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; if barrier contraceptives are being used, these must be continued throughout the trial by both sexes; hormonal contraceptives are not acceptable as a sole method of contraception; (women of childbearing potential must have a negative urine or serum pregnancy test within  days prior to study entry; pregnancy test must be repeated if performed >  days before administration of MGCD)
Women who are pregnant or breast feeding or adults of reproductive potential not employing an effective method of birth control; double barrier contraceptives must be used through the trial by both sexes; oral, implantable, or injectable contraceptives are not considered effective for this study
Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; barrier contraceptives must be used throughout the trial by both sexes; hormonal contraceptives are not acceptable as a sole method of contraception; (women of childbearing potential must have a negative urine or serum pregnancy test within  days prior to administration of everolimus and sorafenib)
Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; if barrier contraceptives are being used, these must be continued throughout the trial by both sexes; hormonal contraceptives are not acceptable as a sole method of contraception; (women of childbearing potential must have a negative urine or serum pregnancy test within  days prior to administration of EVEROLIMUS)
Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; adequate contraception must be used throughout the trial and for  weeks after the last dose of study drug, by both sexes; (women of childbearing potential must have a negative urine or serum pregnancy test within  days prior to administration of study drug)
Women of childbearing potential must have a negative urine or serum pregnancy test within  days prior to administration of everolimus; if barrier contraceptives are being used, these must be continued throughout the trial by both sexes and continue use for  weeks after completing treatment; hormonal contraceptives are not acceptable as a sole method of contraception
Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; two acceptable forms of contraceptives must be continued throughout the trial by either sex; hormonal contraceptives are not acceptable as a sole method of contraception (women of childbearing potential must have a negative serum pregnancy test within  days prior to day  of study drug)
Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; two acceptable forms of contraceptives must be continued throughout the trial by either sex and for  months ( days) following last dose of either drug; hormonal contraceptives are not acceptable as a sole method of contraception; (women of childbearing potential must have a negative serum pregnancy test within  days prior to day  of study drug)
Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; adequate contraception must be used throughout the trial and for  weeks after the last dose of study drug, by both sexes; (women of childbearing potential must have a negative urine or serum pregnancy test within  days prior to administration of everolimus)
Female patients who are pregnant or breastfeeding, or adults of reproductive potential who are not using effective birth control methods; adequate contraception must be used throughout the trial and for  weeks after the last dose of study drug, by both sexes; women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test within  days prior to everolimus initiation
Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; adequate contraception must be used throughout the trial and for  weeks after the last dose of study drug by both sexes
Women who are pregnant or breast feeding or adults of reproductive potential not employing an effective method of birth control; double barrier contraceptives must be used through the trial by both sexes; oral, implantable, or injectable contraceptives may be affected by cytochrome P interactions, and are therefore not considered effective for this study
Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; if barrier contraceptives are being used, these must be continued throughout the trial by both sexes; hormonal contraceptives are not acceptable as a sole method of contraception (women of childbearing potential must have a negative urine or serum pregnancy test within  days prior to administration of EVEROLIMUS)
Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; adequate contraception must be used throughout the trial and for  weeks after the last dose of study drug, by both sexes (women of childbearing potential [WOCBP] must have a negative urine or serum pregnancy test within  days prior to administration of RAD)
